NF2-Associated Meningiomas: From Omics Discovery to Targeted Therapy

NF2 相关脑膜瘤：从组学发现到靶向治疗

基本信息

批准号：
10640996
负责人：
VIJAYA RAMESH
金额：
$ 63.28万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-01 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10640996
关键词：
14q APLN gene Acoustic Neuroma Adult Alleles Anaplastic Meningioma Animal Model Arachnoid mater Back Benign Meningiomas Biological CRISPR/Cas technology Cell Line Cell model Cells Clinical Clinical Trials Collaborations Dasatinib Data Drug Combinations Drug Screening Drug Targeting ERBB3 gene Enzymes Eph Family Receptors Exhibits FRAP1 gene Family Future Genetic Heterogeneity Genetic Transcription Genomic Instability Growth Growth Factor Heregulin Human IGF1R gene Implant In Vitro Intracranial Neoplasms Ligands Luciferases Maximum Tolerated Dose Measures Modeling Monitor Morbidity - disease rate Mus Mutation Names National Center for Advancing Translational Sciences Neuregulins Neurofibromatosis 2 Null Lymphocytes Ohio Operative Surgical Procedures Outcome Study Pathway interactions Pediatric Hospitals Pharmaceutical Preparations Pharmacologic Substance Pharmacotherapy Phosphotransferases Proliferating Proteasome Inhibitor Proto-Oncogene Protein c-kit Public Health Publishing Radiation Randomized Receptor Protein-Tyrosine Kinases Regulation Research Resected Role SDZ RAD Screening Result Signal Pathway Signal Transduction System Systemic Therapy Testing Translating Tumor Suppressor Genes Ubiquitin Ubiquitin-Activating Enzymes United States National Institutes of Health Up-Regulation Work antitumor effect bioluminescence imaging chromosome 22q loss clinical care clinical development comparative genomic hybridization cytotoxic drug efficacy effective therapy follow-up genome editing heparin-binding EGF-like growth factor in vivo in vivo Model in vivo evaluation inhibitor mTOR Inhibitor member meningioma mortality mouse model multicatalytic endopeptidase complex neoplastic cell novel novel therapeutic intervention pre-clinical response single-cell RNA sequencing skull base small molecule inhibitor src-Family Kinases targeted treatment therapeutic target transcriptome transcriptome sequencing tumor tumor growth tumor heterogeneity

项目摘要

Neurofibromatosis 2 (NF2) is characterized by vestibular schwannomas, and meningiomas that show loss of the NF2 tumor suppressor gene. Meningiomas arise from meningothelial arachnoid cap cells and are the most common primary intracranial tumors in adults. NF2 inactivation is frequently associated with sporadic meningiomas, particularly in primary atypical (WHO grade II) tumors. Meningiomas that progress despite surgery and radiation are responsible for significant morbidity and mortality. Therefore, effective systemic therapies are greatly needed. For meningioma modeling and preclinical drug screening, we employ human primary meningioma (MN) cell lines derived from surgically resected tumors and CRISPR-Cas9 genome-edited isogenic, human arachnoidal cell lines (ACs) that either express or lack NF2. Employing these models, we established that NF2-deficient meningiomas reveal aberrant activation of mTORC1/mTORC2 signaling, which led to clinical trials for NF2 and meningiomas. Recently, we undertook large-scale kinome, transcriptome and drug screening studies in our AC and MN cell models to identify other potential targets. Kinome and transcriptome data revealed increased activation and expression of several EPH receptor family tyrosine kinases (EPH-RTKs), Src family kinase members (SFKs) and c-KIT, which are all targets of dasatinib, which is recently published. Our ‘omics approach also identified other interesting candidates, including ligands NRG1, HBEGF and apelin, and AMPK-related kinases, particularly NUAK2, to be consistently upregulated in the kinome and transcriptome of NF2-null AC/MN cells. Our recent results suggest that NRG1 expression and ERBB3 signaling is regulated by mTORC1 signaling. We plan to examine whether NRG1 alone or factors such as HBEGF and APLN are also regulated by mTOR or play a role in downstream signaling in NF2-null MN cells. We propose to understand the mechanism and biological significance of elevated expression and activation of NUAK2 in meningioma. Further, our large-scale drug screening efforts, in collaboration with NIH-NCATS, revealed a set of proteasome pathway related drugs exhibiting cytotoxic effects in NF2-null cells. Here we propose to examine three different drugs targeting the proteasome (provided by Millennium-Takeda Pharmaceuticals), alone and combined with TAK-228 (mTOR inhibitor) in 5 grade I, 5 grade II and 5 grade III MN lines with NF2 loss. More importantly, we propose to undertake single cell RNAseq along with array CGH in NF2-deficient meningiomas and their corresponding primary cell lines to define tumor heterogeneity and correlate with drug response. Anti-tumor efficacy of proteasome drugs will also be evaluated in orthotopic NF2- deficient benign and malignant meningioma models. Our overall approach of (i) leveraging the ‘omics and drug screening results, (ii) characterizing tumor heterogeneity and correlating with drug response, and (iii) testing potential drugs in orthotopic NF2-deficient in vivo models is timely, novel and will provide a framework to pursue new avenues in NF2 and meningioma research for clinical care.

神经纤维瘤病2（NF2）的特征是前庭schwannomas，脑膜瘤显示出显示的损失 NF2肿瘤抑制基因。脑膜膜瘤来自脑膜皮蛛网膜帽细胞，是最大的成人常见的原发性颅内肿瘤。 NF2失活经常与零星有关脑膜瘤，特别是在原发性非典型（WHO II级）肿瘤中。前进的脑膜瘤手术和射击负责大量发病率和死亡率。因此，有效的系统性非常需要疗法。对于脑膜瘤建模和临床前药物筛查，我们员工人类源自手术切除的肿瘤和CRISPR-CAS9基因组编辑的原发性脑膜瘤（MN）细胞系表达或缺乏NF2的等源性人蛛网膜细胞系（AC）。采用这些模型，我们确定NF2缺乏脑膜瘤显示MTORC1/MTORC2信号的异常激活，这导致NF2和脑膜瘤的临床试验。最近，我们进行了大规模的Kinome，转录组和在我们的AC和MN细胞模型中进行药物筛查研究，以鉴定其他潜在靶标。 Kinome和转录组数据显示，几种EPH受体家族酪氨酸的激活和表达增加激酶（EPH-RTKS），SRC家族激酶成员（SFK）和C-KIT，都是Dasatinib的靶标，是最近出版。我们的'Omics方法还确定了其他有趣的候选人，包括配体NRG1， HBEGF和APELIN，以及与AMPK相关的激酶，尤其是NUAK2，将在 NF2-NULL AC/MN细胞的Kinome和转录组。我们最近的结果表明NRG1表达和 ERBB3信号通过MTORC1信号传导调节。我们计划检查单独的NRG1还是此类因素由于HBEGF和APLN也受MTOR的调节或在NF2-NULL MN细胞中的下游信号传导中起作用。我们建议了解升高表达和激活的机制和生物学意义 NUAK2在脑膜瘤中。此外，我们与NIH-NCATS合作的大规模药物筛查工作，揭示了一组蛋白酶体途径相关的药物在NF2无效细胞中表现出细胞毒性作用。我们在这里提议检查针对蛋白酶体的三种不同药物（由千年takeda提供 Pharmaceuticals），单独使用5级I，5级和5级III的TAK-228（MTOR抑制剂）合并 MN线有NF2损失。更重要的是，我们建议与阵列CGH一起进行单细胞RNASEQ 在NF2缺乏脑膜瘤及其相应的原始细胞系中，以定义肿瘤异质性和与药物反应相关。蛋白酶体药物的抗肿瘤效率也将在原位NF2-中进行评估防御性良性和恶性脑膜瘤模型。我们（i）利用'omics and Drug的总体方法筛查结果，（ii）表征肿瘤异质性并与药物反应相关，以及（iii）测试原位NF2缺乏体内模型中的潜在药物是及时的，新颖的，将为框架提供一个框架在NF2和脑膜瘤研究中追求新的途径，以进行临床护理。

项目成果

期刊论文数量（4）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.

DOI：
10.1074/jbc.ra120.014960
发表时间：
2021-01
期刊：
The Journal of biological chemistry
影响因子：
0
作者：
Beauchamp RL;Erdin S;Witt L;Jordan JT;Plotkin SR;Gusella JF;Ramesh V
通讯作者：
Ramesh V

Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.

蛋白酶体途径抑制作为 NF2 相关脑膜瘤和神经鞘瘤的潜在疗法。

DOI：
10.1093/neuonc/noad037
发表时间：
2023
期刊：
Neuro-oncology
影响因子：
15.9
作者：
Bhattacharyya,Srirupa;Oblinger,JanetL;Beauchamp,RobertaL;Yin,Zhenzhen;Erdin,Serkan;Koundinya,Priya;Ware,AnnaD;Ferrer,Marc;Jordan,JustinT;Plotkin,ScottR;Xu,Lei;Chang,Long-Sheng;Ramesh,Vijaya
通讯作者：
Ramesh,Vijaya

Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2.

DOI：
10.1016/j.omtm.2022.06.012
发表时间：
2022-09-08
期刊：
MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT
影响因子：
0
作者：
Prabhakar, Shilpa;Beauchamp, Roberta L.;Cheah, Pike See;Yoshinaga, Akiko;Abou Haidar, Edwina;Lule, Sevda;Mani, Gayathri;Maalouf, Katia;Stemmer-Rachamimov, Anat;Jung, David H.;Welling, Bradley;Giovannini, Marco;Plotkin, Scott R.;Maguire, Casey A.;Ramesh, Vijaya;Breakefield, Xandra O.
通讯作者：
Breakefield, Xandra O.